Pulmonary Fibrosis & Hypertension

Diffuse parenchymal lung disease

Between September 2015 and August 2016 there were >1500 publications in the field of diffuse parenchymal lung diseases (DPLDs). For the Clinical Year in Review session at the European Respiratory Society Congress that was held…

Alveolar stem cell failure implicated in pulmonary fibrosis

The failure of type 2 alveolar epithelial cells appears to be a major cause of pulmonary fibrosis, according to a report published online in Nature Medicine.

Riociguat shows benefit in PAH with poor response to PDE inhibitors

LOS ANGELES – Pulmonary artery hypertension patients who have an insufficient response to phosphodiesterase inhibitors may benefit from a switch to riociguat (Adempas), based on results from a…

Median survival only 4 years, worse with monotherapy